RFI: High Performance Antigen Diagnostics

Request for Information Description

The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high-performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.

This RFI seeks to understand both currently available systems and emerging technologies, including integrated platforms and enabling components, that can bring ultra-sensitive performance into smaller, faster, more deployable, and ideally multiplexed platforms or formats.

Respondents do not have to be a member of the RRPV consortium to submit a response for this RFI; however, they must be a member of the consortium to respond to any future request for project proposals (RPP) for this requirement.